Sclc paper

Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer SCLCmedulloblastoma and others.

advances in small cell lung cancer

Both the absolute and relative frequencies of lung cancer have risen dramatically. Currently, studies utilizing genomic and proteomic profiling technology are providing further insights into SCLC biology.

Lung cancer researchers and the pharmaceutical companies appear to be living in the land of the Lotus-Eaters. There is currently no consensus on how patients who relapse, or do not completely respond, after first-line treatment should be managed, although there is some evidence that second-line therapy with the same agents is worthwhile National Institute for Health and Clinical Excellence, ; novel agents are under investigation.

Certain intrinsic SCLC features serve as limitations in our efforts toward demonstrating its biological heterogeneity. There have been advances in the clinic since then, including the approval of topotecan for recurrent SCLC and the application of new radiation therapy strategies, but despite these advances the outlook for patients afflicted with SCLC remains dismal 3 - 8.

Advanced small cell lung cancer

This further supports the need for initiatives that improve early presentation and diagnosis. Ultimately, combined chemo-radiotherapy treatment protocols were tested 9 and incorporated into the treatment of LD-SCLC As trials tend to include younger patients with relatively good performance status, the median survival for the full spectrum of patients is likely to be less. We used Cox regression to estimate survival from the date of diagnosis according to whether or not chemotherapy or chemo-radiotherapy were given, route of referral and whether or not the patient was first seen in a chemotherapy trust. Considering the low possibility of a positive phase II trial going forward to a successful phase III trial 58 , these remarkably low numbers are clearly insufficient. However, since then our knowledge regarding SCLC has entered a dormant state. The majority of patients relapse within 6 months after completion of initial treatment, leading to a median survival range of 15 to 20 months and eight to 13 months for patients with LD and ED, respectively The results were very similar when we excluded the effect of immortal time bias by assessing survival in those who had chemotherapy from the end of their last recorded cycle Supplementary Table A. By employing analogical reasoning, one should expect that SCLC research would have advanced at the same pace. We used a binary variable for time to treatment using above or below the median number of days from diagnosis to first chemotherapy dose. As previously mentioned, resection is indicated in the rare case of a patient presenting with a small peripheral primary lesion Furthermore, the paradigm of NSCLC has taught us that driver mutations may be rare genetic defects, found only in a small fraction of tumors. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made.

We calculated the proportion of people who had chemotherapy according to the patient, tumour and trust characteristics defined above and used multivariate logistic regression to estimate the odds of receiving chemotherapy according to the same characteristics.

Abstract Small cell lung cancer SCLC is an aggressive malignancy with a distinct natural history and dismal prognosis.

It is believed that only a small subset of the numerous somatic mutations observed in SCLC are crucial for tumor cell proliferation and progression. We enhanced our chemotherapy records by comparing records in HES and the NLCA and found that use of a single data set underestimated the proportion of people who received chemotherapy.

Discussion We have used current English data to describe which patients with SCLC received chemotherapy treatment and give real-life estimates of survival.

biology of small cell lung cancer

Strengths and limitations The main strengths of this study are the large sample size and the validity of the database Rich et al, b.

Conclusion These national data reflect the decisions that were made about chemotherapy treatment in clinical practice in England.

Rated 5/10 based on 87 review
SCLC CTC paper